Overview

• Tempus AI reported Q1 2025 revenue of $255.74 million, exceeding analyst expectations of $248.13 million, with a 75.4% year-over-year growth.
• The company posted a narrower-than-expected adjusted loss of $0.24 per share, beating estimates of a $0.27 per share loss.
• Full-year 2025 revenue guidance was raised from $1.24 billion to $1.25 billion, representing approximately 80% annual growth.
• Tempus launched Notetaker, an AI clinical assistant designed to streamline psychiatric documentation by recording sessions and generating notes for electronic health records.
• Strategic collaborations with AstraZeneca and Pathos AI were deepened under a $200 million agreement to develop a multimodal oncology foundation model, leveraging Tempus' de-identified data.